HIGHLIGHTS
- who: Daniela Sieghart and colleagues from the Halmstad University, Sweden Hospital Clinic of Barcelona, Spain have published the research: The diagnostic and prognostic value of IgG and IgA anti-citrullinated protein antibodies in patients with early rheumatoid arthritis, in the Journal: (JOURNAL)
SUMMARY
Treatment information was available for all patients and used to calculate drug survival times to methotrexate (MTX) (n=144) and the first anti-TNF biological therapy (n=142): 78 patients were treated with Adalimumab, 38 with Etanercept, 14 with Golimumab and 12 patients received Infliximab; out of these 142 patients . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.